Home›Bimekizumab

Bimekizumab

Also known as: Bimzelx

Route: Subcutaneous

2 interactions on record

Bimekizumab has 2 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Cyclosporine, Warfarin. Patients taking Bimekizumab should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Moderate: 2

Moderate (2)

Bimekizumab + Cyclosporine— BIMKELX may modulate serum cytokine levels, altering CYP450 enzyme formation and affecting cyclosporine metabolism. Moni…
Bimekizumab + Warfarin— BIMKELX may modulate serum cytokine levels, altering CYP450 enzyme formation and affecting warfarin metabolism. Monitor …

Bimekizumab + Cyclosporine🟡Moderate

BIMKELX may modulate serum cytokine levels, altering CYP450 enzyme formation and affecting cyclosporine metabolism. Monitor drug concentration and consider dosage modification.

Bimekizumab + Warfarin🟡Moderate

BIMKELX may modulate serum cytokine levels, altering CYP450 enzyme formation and affecting warfarin metabolism. Monitor for effect upon initiation or discontinuation.

Contraindications

4 CONTRAINDICATIONS None. None. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to BIMZELX during pregnancy. For more information, healthcare providers or patients can contact the Organization of Teratology Information Specialists (OTIS) AutoImmune Diseases Study at 1-877-311-8972 or visit http://mothertobaby.org/pregnancy-studies/. Risk Summary Available data from case reports on BIMZELX use in pregnant women are insufficient to evaluate for a drug associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Transport of human IgG antibody across the placenta increases as pregnancy progresses and peaks during the third trimester; therefore, BIMZELX may be transmitted from the mother to the developing fetus (see Clinical Considerations ) . In an enhanced pre- and postnatal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of bimekizumab-bkzx during the period of organogenesis through parturition at doses up to 38 times the maximum recommended human dose (MRHD) (see Data ) . All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions: Because bimekizumab-bkzx may interfere with immune response to infections, risks and benefits should be considered prior to administering live vaccines to infants exposed to BIMZELX in utero. There are no data regarding infant serum levels of bimekizumab-bkzx at birth and the duration of persistence of bimekizumab-bkzx in infant serum after birth. Although a specific timeframe to delay live virus immunizati

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.